Rosetta Genomics Ltd.
Other OTCTotal Valuation
Rosetta Genomics Ltd. carries a market capitalization of 593.00, placing it among publicly traded companies globally. Its enterprise value stands at 102.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 593.00 |
| Enterprise Value | 102.42M |
Share Statistics
Rosetta Genomics Ltd. currently has 1.84M shares outstanding.
| Shares Outstanding | 1.84M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 14.50, and the price-to-book ratio stands at -0.68.
| PE Ratio | N/A |
| PS Ratio | 14.50 |
| PB Ratio | -0.68 |
| P/TBV Ratio | 23.72 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 14.17 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Rosetta Genomics Ltd. maintains a current ratio of 2.50, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.50 |
| Quick Ratio | 2.39 |
| Debt / Equity | 85.92 |
| Debt / EBITDA | -0.24 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -94.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 6,000.00 |
| Effective Tax Rate | N/A |
Income Statement
Over the trailing twelve months, Rosetta Genomics Ltd. generated 7.23M in revenue and converted that into -16.23M in net income, yielding earnings per share of -9.29. EBITDA reached -15.53M, while operating income came in at -15.53M.
| Revenue | 7.23M |
| Gross Profit | 1.28M |
| Operating Income | -15.53M |
| Pretax Income | -16.13M |
| Net Income | -16.23M |
| EBITDA | -15.53M |
| EBIT | -15.53M |
| Earnings Per Share (EPS) | -9.29 |
Balance Sheet
Rosetta Genomics Ltd. holds 6.16M in cash and equivalents against 3.80M in total debt, resulting in a net debt position of -2.49M. Total book value stands at -153.06M, with working capital of 5.71M providing operational flexibility.
| Cash & Cash Equivalents | 6.16M |
| Total Debt | 3.80M |
| Net Debt | -2.49M |
| Equity (Book Value) | -153.06M |
| Book Value Per Share | -88.34 |
| Working Capital | 5.71M |
Margins
Rosetta Genomics Ltd. operates with a gross margin of 17.71, reflecting its pricing power and cost economics. The operating margin of -214.93 and net profit margin of -224.65 provide insight into operational efficiency.
| Gross Margin | 17.71 |
| Operating Margin | -214.93 |
| Pretax Margin | -223.19 |
| Profit Margin | -224.65 |
| EBITDA Margin | -214.93 |
Stock Splits
Rosetta Genomics Ltd.'s most recent stock split took place on March 17, 2017 with a 12:1 split ratio.
| Last Split Date | 3/17/2017 |
| Split Ratio | 12:1 |
Scores
Rosetta Genomics Ltd. posts an Altman Z-Score of -13.09, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.09 |